About

About CTCELLS About CTCELLS CTCELLS is an innovative biotechnology company striving for a total solution for cancer. With platform technologies in both therapeutics and diagnostics, the RACE platform is designed to deliver safer and more effective immunotherapies by optimizing the selection and administration of treatment based on a patient's unique immunological profile. The TRACE Platform, on the other hand, is a cutting-edge liquid biopsy system that captures all types of Circulating Tumor Cells (CTCs). This allows for more precise diagnostics and treatment planning, targeting a range of cancer types. CTCELLS is committed to improving patient outcomes by integrating the latest in scientific research and technology into their products. CTCELLS is an innovative cancer diagnostics and drug development company founded on the belief that effective cancer care requires solutions tailored to each individual. Powered by Circulating Tumor Cell (CTC) liquid biopsy, CTCELLS enables automated isolation of diverse CTC subtypes to better capture the full biological heterogeneity of cancer. To translate these insights into actionable research and clinical value, CTCELLS integrates its proprietary Continuous Centrifugal Microfluidics (CCM) technology for robust, automated CTC processing, lossless cell staining enabled by hydrogel-based HypICC to preserve cellular information for downstream analysis, and single-cell picking to support precise molecular profiling and functional characterization. By connecting cancer-specific cellular characteristics with the most suitable therapies, CTCELLS is committed to improving patient outcomes and accelerating the development of next-generation treatments, bringing new hope to patients facing difficult-to-treat cancers. CTCELLS is an innovative biotechnology company striving for a total solution for cancer. With platform technologies in both therapeutics and diagnostics, the RACE platform is designed to deliver safer and more effective immunotherapies by optimizing the selection and administration of treatment based on a patient's unique immunological profile. The TRACE Platform, on the other hand, is a cutting-edge liquid biopsy system that captures all types of Circulating Tumor Cells (CTCs). This allows for more precise diagnostics and treatment planning, targeting a range of cancer types. CTCELLS is committed to improving patient outcomes by integrating the latest in scientific research and technology into their products.